Role of nafarelin in the management of endometriosis.

The Journal of reproductive medicine · 1989 · vol. 34(12 Suppl) , pp. 1021–4 · PMID:2533616 · W2428626666
article OA: closed CC0 ⤵ 11 in-corpus citations
View on OpenAlex View on PubMed
AI-generated summary by claude@2026-06, 2026-06-08

Nafarelin relieved endometriosis symptoms, reduced laparoscopic scores, and improved fertility in women, with side effects limited to hypoestrogenism.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

A large, multicenter, double-blind clinical trial established that the gonadotropin releasing hormone analog nafarelin relieves clinical symptoms, decreases laparoscopic scores and improves fertility in women with endometriosis. Side effects were limited to those attributable to hypoestrogenism.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Endometriosis Gonadotropin-Releasing Hormone Double-Blind Method Endometriosis Estrogens Estrogens Female Fertility Fertility Gonadotropin-Releasing Hormone Gonadotropin-Releasing Hormone Gonadotropin-Releasing Hormone Humans Multicenter Studies as Topic Nafarelin Randomized Controlled Trials as Topic

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

Cited by (11)

Source provenance

europepmc
last seen: 2026-06-20T06:14:18.781669+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:09:10.744835+00:00
License: CC0 · commercial use OK